Entera Bio Ltd

ENTX

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    22

Stocks News & Analysis

stocks

Materially undervalued ASX tech share

Long reinvestment runway supports our thesis on ASX technology company.
stocks

For US software stocks, it’s been an AI bust, not a boom

Once-hot software names are lagging. Are they good buys?
stocks

Finding value in the Aussie mining sector

Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,824.2019.20-0.22%
CAC 408,012.0552.380.66%
DAX 4023,405.42166.240.72%
Dow JONES (US)46,448.27202.860.44%
FTSE 1009,575.4840.570.43%
HKSE25,894.55178.050.69%
NASDAQ22,872.01598.922.69%
Nikkei 22548,659.5233.640.07%
NZX 50 Index13,480.4319.42-0.14%
S&P 5006,705.120.000.00%
S&P/ASX 2008,537.0026.70-0.31%
SSE Composite Index3,870.0233.260.87%

Market Movers